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Study goal
The present project aims at evaluating the cytocompatibility and printability of
a new composite material, based on a mixture of a new methacrylate-based
monomer developed within a CTI project (18514.1 PFLS-LS) and glass-ceramic
powder supplemented with co- and photo-initiators (patent in preparation).
This study is the basis to demonstrate the suitability of the biomaterial, for
biomedical applications, such as stent, orthopedic implants and hearing aid
components, as well as for 3D (bio)printing
Key findings
 Cultivation, proliferation and differentiation of three different human cell
types were successfully established on composite material discs (1cm
diameter, 1mm height). Biological activity was shown
 The material is suitable for 3D (bio)printing, printing protocols were
established
 The new composite material is suitable for cell and tissue interaction in
biomedical applications
Conclusions
The new composite material is not only cytocompatible (DIN EN Iso 10993-5), but also allows the biological activity of human cells (spreading, proliferation and 
differentiation). Moreover, preliminary studies demonstrate the suitability of the material for (bio)printing. The composite shows high potential as biomaterial for 3D 
printing in different biomedical applications
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Project data
Figure 1: SAOS-2 (osteoblasts), NHDF (fibroblasts) and HUVEC (endothelial cells) seeded onto 
discs and cultivated up to 7 days before staining for F-actin (green signal, fluorescent phallacidin) 
and nuclei (blue signal, DAPI). Scale bar, 100µm 
Figure 2: Metabolic cell activity detected with PrestoBlue at day1, 
3 and 7. Unpaired T-test, p-values: ** p<0.01; *** p<0.001; 
**** p<0.0001
 All cell types 
adhere, spread 
and proliferate on 
the biomaterial 
over time
 Cells are able to 
form a monolayer 
at day 7 on top of 
each discs
Cells adhesion and proliferation
Biological cell activity
Biomaterial printability
 SAOS-2 express 
ALP osteogenic 
marker
 Fibroblasts 
express and secret 
collagen type I
 HUVEC express 
CD31 with a 
tendency for cell 
alignment at day 7
 The composite biomaterial is printable in a precise manner
 Well defined structures/models with high resolution can be obtained
Figure 3: 
A, ALP activity normalized to total protein amount on SAOS-2 culture. Unpaired T-test, *** p<0.001
B, Coll I expression in fibroblasts cultures vs metabolic activity 
C, CD31 immunocytochemistry analysis in HUVEC cells cultivated up to 7 days (red signal). Nuclei in blue (DAPI). Scale bar, 50µm
Figure 4: 3D structures printed with 
3DDiscovery (regenHU) with direct dispensing in 
a layer-by-layer fashion. A-D, 3 layers models; 
E, 10 layers model. Scale bar, 1000µm
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 3D printed models tested are 
stable showing rigid shape 
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